Health Care · Biotechnology
Vertex Pharmaceuticals: revenue, profit and cash flow
In fiscal 2025, Vertex Pharmaceuticals had revenue of $12B, up 27.8% a year on average since 2015, and net income of $3.95B (32.9% of revenue). It has 7% more shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +8.9% vs 2024
- Ticker
- VRTX · Nasdaq
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- Boston, Massachusetts
- Founded
- 1989
- In the S&P 500 since
- September 23, 2013
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Vertex Pharmaceuticals Inc / Ma · CIK 0000875320
Revenue and net income
Revenue went from $176M in 2008 to $12B in 2025. Net loss in 2008–2010, 2012–2016, 2024.
Diluted earnings per share
Diluted EPS went from −$3.27 in 2008 to $15.32 in 2025.
Shares outstanding
6.9% more shares in 2025 than in 2015 (241M → 258M): new shares outweighed buybacks.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $3.19B in 2025, 26.6% of revenue. Negative in 2008–2010, 2013–2015, 2024.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|
| 2025 | $12B | $3.95B | 32.9% | $15.32 | 258M | $3.63B | $438M | $3.19B |
| 2024 | $11B | −$536M | −4.9% | −$2.08 | 258M | −$493M | $298M | −$790M |
| 2023 | $9.87B | $3.62B | 36.7% | $13.89 | 260M | $3.54B | $200M | $3.34B |
| 2022 | $8.93B | $3.32B | 37.2% | $12.82 | 259M | $4.13B | $205M | $3.93B |
| 2021 | $7.57B | $2.34B | 30.9% | $9.01 | 260M | $2.64B | $235M | $2.41B |
| 2020 | $6.21B | $2.71B | 43.7% | $10.29 | 263M | $3.25B | $260M | $2.99B |
| 2019 | $4.16B | $1.18B | 28.3% | $4.51 | 261M | $1.57B | $75.4M | $1.49B |
| 2018 | $3.05B | $2.1B | 68.8% | $8.09 | 259M | $1.27B | $95.4M | $1.17B |
| 2017 | $2.49B | $263M | 10.6% | $1.04 | 253M | $845M | $99.4M | $746M |
| 2016 | $1.7B | −$112M | −6.6% | −$0.46 | 245M | $236M | $56.6M | $180M |
| 2015 | $1.03B | −$556M | −53.9% | −$2.31 | 241M | −$365M | $45.3M | −$411M |
| 2014 | $580M | −$739M | −127.2% | −$3.14 | 235M | −$573M | $51.2M | −$624M |
| 2013 | $1.21B | −$445M | −36.7% | −$1.98 | 225M | −$60.7M | $51.4M | −$112M |
| 2012 | $1.53B | −$107M | −7.0% | −$0.50 | 215M | $268M | $71.1M | $197M |
| 2011 | $1.41B | $29.6M | 2.1% | $0.14 | 209M | $144M | $34.6M | $109M |
| 2010 | $143M | −$755M | −526.3% | −$3.77 | 200M | −$635M | $38.1M | −$673M |
| 2009 | $102M | −$642M | −630.3% | −$3.71 | 173M | −$428M | $23.5M | −$451M |
| 2008 | $176M | −$460M | −262.0% | −$3.27 | 141M | −$226M | $32.2M | −$259M |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- No dividends per share in the filings data. Usually that means no dividend, but some companies report theirs in a form the data do not capture.
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Biotechnology companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.